This is a newer option, so usually it is offered only through research studies (clinical trials). At Seattle Children’s, I-131-MIBG therapy may be an option for children with high-risk neuroblastoma in these ways:
- A “compassionate use” option for children with disease that does not respond well to treatment (refractory) or that has come back (recurrent). This means the U.S. Food and Drug Administration lets these patients take the drug before it is approved and without taking part in a clinical trial. Our doctors have worked with the Children’s Oncology Group and New Approaches to Neuroblastoma Therapy to make I-131-MIBG available.
- A clinical trial for children who are newly diagnosed with high-risk neuroblastoma.
In the future, I-131-MIBG therapy may be used as part of the treatment for all children with high-risk neuroblastoma. Before this can happen, researchers need more research results to tell whether standard treatment plus I-131-MIBG therapy may work at least as well as standard treatment alone.